This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Competition Law in the Pharmaceutical Sector Conference
December 2022
Venue TBCBrussels, Belgium

December 2022
Venue TBC,
Brussels, Belgium

Competition Law in the Pharmaceutical Sector

Dissect the competition authorities' newly aggressive approach to the pharma sector including the CMA's new cases, developments in pricing, Article 22 guidance, distribution, follow on damages, patents & much more during this essential 1-day update.

Thank you to all those who attended in 2021!

We have started putting the 2022 programme together.

If you would like to be kept up to date, you can register your interest by downloading last year's agenda here.

Your Essential 1-Day Update on Competition Law in the Pharma Sector:

Enforcement Priorities: EU & UK

First hear directly from the Commission on their priorities, then ensure you are up to date with the CMA's recent enforcement including Nortriptyline CAT judgment; Hydrocortisone and Liothyronine CMA decisions; and Phenytoin remittal.

Mergers in the Pharma Sector

During this essential update you'll analyse jurisdiction issues including Article 22 and Illumina-Grail, new theories of harm in merger cases including the new working group established between the US FTC, EC, CMA and Canadian Bureau, killer acquisitions and pipeline products and vertical mergers in the pharma sector.

Distribution & VBER

Gain a practical update on current distribution challenges including a review of the Vertical Block Exemption Regulation and its implication for the pharma sector. Plus, practical strategies when dealing with online sales and parallel trade.


Review horizontal guidelines and their likely impact on the pharma sector and consider practical challenges and strategies to overcome them in cooperation and collaboration agreements.

Pricing in Practice

Join this interactive panel session to discuss practical consequences of recent exclusionary pricing cases and to consider what price increases are permissible in light of them. Then, consider competition law challenges raised by indication-based pricing and pricing of combination therapies.


Discuss recent developments in patents including patent pooling, the Copaxone Investigation and reverse patent settlements - including their implications for patent filing strategies.

B Vos

Eli Lilly & Co

Of great practical relevance for in-house counsel in the pharmaceutical sector.